Moderate

Alcohol-related liver disease — management

ArLD · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A spectrum from steatosis through steatohepatitis to fibrosis and cirrhosis driven by chronic alcohol use; abstinence is the single most effective intervention and alters prognosis at every stage.

Red flags

  • Jaundice with coagulopathy (severe alcohol-related hepatitis/decompensation)
  • Encephalopathy or GI bleeding
  • Features of Wernicke's (confusion, ophthalmoplegia, ataxia)
  • Rapidly rising bilirubin

Assessment

Differential diagnosis

  • MASLD/metabolic steatohepatitis
  • Viral hepatitis
  • Haemochromatosis
  • Autoimmune/drug-induced liver injury
  • Acute alcohol-related hepatitis (distinct acute syndrome)

Investigations

  • LFTs (AST:ALT ratio >2 typical), GGT, FBC (macrocytosis, thrombocytopenia)
  • Liver screen to exclude other causes (viral, autoimmune, iron, ceruloplasmin)
  • Transient elastography (FibroScan) for fibrosis staging
  • Ultrasound ± cross-sectional imaging; AFP if cirrhotic (HCC surveillance)
  • Alcohol use assessment (AUDIT), nutritional and thiamine status

Management

  • Establish diagnosis and stage fibrosis non-invasively; exclude co-existing liver disease
  • Support alcohol abstinence — the decisive intervention — with specialist alcohol services
  • Manage/anticipate alcohol withdrawal with a symptom-triggered benzodiazepine regimen
  • Give parenteral thiamine to prevent Wernicke's encephalopathy before carbohydrate
  • Optimise nutrition — high calorie/protein intake, treat micronutrient deficiencies
  • Treat the metabolic co-factors (obesity, diabetes) that accelerate fibrosis
  • Vaccinate against hepatitis A and B
  • Screen for and manage cirrhosis complications (varices, ascites, encephalopathy)
  • Enrol cirrhotic patients in 6-monthly HCC surveillance ultrasound
  • Identify acute alcohol-related hepatitis (distinct severe syndrome) needing specific assessment
  • Provide long-term relapse-prevention pharmacotherapy and psychosocial support
  • Refer for transplant assessment in decompensated disease with abstinence

Drugs & doses

Pabrinex (thiamine-rich B/C vitamins) IV then oral thiamine 100 mg three times daily
Chlordiazepoxide 10–40 mg PO (symptom-triggered withdrawal regimen)
Acamprosate 666 mg PO three times daily (relapse prevention)
Baclofen 5–10 mg PO three times daily (relapse prevention in cirrhosis)

Disposition

Joint hepatology and alcohol-services management; admit decompensation/withdrawal; transplant referral for abstinent decompensated patients.

Complications & pitfalls

  • Cirrhosis and portal hypertension
  • Hepatocellular carcinoma
  • Wernicke-Korsakoff syndrome
  • Alcohol withdrawal seizures/delirium tremens
  • Malnutrition and sarcopenia

Exam pearls

  • Give thiamine before any glucose to avoid precipitating Wernicke's encephalopathy
  • An AST:ALT ratio >2 with raised GGT and macrocytosis points to alcohol as the cause
  • Abstinence improves survival at every disease stage, even in advanced cirrhosis
  • Baclofen is a preferred relapse-prevention agent in decompensated cirrhosis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.